AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Oncolytic virus CF33-hNIS (VAXINIA) is IMU’s lead candidate.
- CF33 and the MAST trial design and targets were presented at international event, ASCO GI Cancers Symposium.
- Preliminary data has demonstrated encouraging anti-tumour activity.
Imugene Limited (ASX: IMU) has shared details of its poster presentation at the ongoing annual international event - ASCO Gastrointestinal Cancers Symposium (ASCO-GI) in San Francisco. Yesterday (18 January 2024), the company presented its poster –
Dr Daneng Li delivered the presentation of the poster. Daneng Li is from the City of Hope National Comprehensive Centre. The presentation included extensive background of CF33-hNIS, the study design, aim of the study, and results observed to date.
Conclusion of the presentation
Preliminary data from the initial three dose levels showed promising anti-tumour activity with CF33 monotherapy. Notably, an individual with cholangiocarcinoma, who got treatment intratumorally retuned an immunological complete response with no known recurrence after 12 months.
CF33-hNIS monotherapy appears to be a potentially secure and effective treatment alternative for gastrointestinal malignancies and warrants additional assessment in biliary tract cancer patients.
Immunological changes in patients responding to CF33-hNIS demonstrates substantial innate and adaptive immune response. This response is known for promoting anti-tumor immunity and emphasises the immunomodulatory capability of the therapy.
IMU share soars
IMU shares jumped almost 10% to trade at AU$0.110 apiece at the time of writing on 19 January 2024.